Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) EBT (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed EBT for 4 consecutive years, with -$23.3 million as the latest value for Q4 2025.

  • For Q4 2025, EBT rose 60.68% year-over-year to -$23.3 million; the TTM value through Dec 2025 reached -$109.3 million, up 44.69%, while the annual FY2025 figure was -$109.3 million, 23.71% down from the prior year.
  • EBT was -$23.3 million for Q4 2025 at Day One Biopharmaceuticals, down from -$19.7 million in the prior quarter.
  • The five-year high for EBT was $35.0 million in Q3 2024, with the low at -$110.8 million in Q2 2024.
  • Historically, EBT has averaged -$39.9 million across 4 years, with a median of -$38.9 million in 2022.
  • The largest annual shift saw EBT soared 175.75% in 2024 before it plummeted 156.33% in 2025.
  • Over 4 years, EBT stood at -$40.1 million in 2022, then crashed by 35.95% to -$54.5 million in 2023, then decreased by 8.78% to -$59.3 million in 2024, then skyrocketed by 60.68% to -$23.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$23.3 million in Q4 2025, -$19.7 million in Q3 2025, and -$30.3 million in Q2 2025.